Ricerca avanzata

Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 Agosto;54(4) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 Agosto;54(4):389-400

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

 

The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 Agosto;54(4):389-400

PRESENT AND FUTURE IN PAEDIATRIC NUCLEAR MEDICINE 

 REVIEW

Modern nuclear medicine evaluation of neuroblastoma

Pflüger T. 1, Schmid I. 2, Coppenrath E. 3, Weiss M. 1

1 Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany;
2 Department of Pediatrics, Ludwig-Maximilians-University of Munich, Munich, Germany;
3 Department of Radiology, Ludwig-Maximilians-University of Munich, Munich, Germany

The neuroblastoma is an embryonic tumor of the peripheral sympathetic nervous system, and is metastatic or otherwise high risk for relapse in nearly 50% of cases, with a long-term survival of <40%. Therefore, exact staging with radiological and nuclear medicine imaging methods is crucial for finding the adequate therapeutic choice. The tumor cells express the norepinephrine transporter, which makes metaiodobenzylguanidine (MIBG), an analogue of norepinephrine, an ideal tumor specific agent for imaging. On the other hand, MIBG imaging has several disadvantages as limited spatial resolution, limited sensitivity in small lesions, need for two or even more acquisition sessions, and a delay between the start of the examination and result. Most of these limitations can be overcome with positron emission tomography (PET) using different radiotracers. Furthermore, MIBG imaging is not sufficient for operative or biopsy planning. With this regard, a combination with morphological imaging methods is indispensable. This article will discuss the therapeutic strategy for primary and follow-up diagnosis in neuroblastoma using different nuclear medicine and radiological imaging methods as well as multimodality imaging.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina